Helicobacter pylori

TL;DR: H. pylori is associated with increased all-cause dementia risk, but the association with Alzheimer’s disease specifically is inconsistent across meta-analyses and disappears in the most recent, best-powered analyses. H. pylori has never been detected in AD brain tissue (it was used as a negative control in PMID:30746447, the landmark P. gingivalis brain study). No RCT has demonstrated that H. pylori eradication prevents or treats AD. Eradication has standard gastroenterology indications; it is not currently recommendable as a cognitive protection strategy.

Evidence Grades

Claim	Grade	Source
H. pylori NOT detected in AD patient CSF	A	PMID:30746447 (negative control)
H. pylori associated with all-cause dementia (not AD specifically)	B	PMID:40958121, PMID:40687714
Meta-analyses: no significant AD-specific association	B	PMID:34559067, PMID:40958121
H. pylori eradication RCT (Kountouras 2009): small, open-label, not replicated	B-	PMID:19240960
OMV → C3-C3aR → glial activation (mouse data)	B	PMID:36792546

Key Facts

• Organism: Helicobacter pylori — gram-negative microaerophilic bacterium; colonizes gastric mucosa via urease-based acid resistance; infects ~44% of global population
• AD brain detection: None reported. In PMID:30746447, H. pylori was explicitly used as a negative control — it was tested in CSF of 10 AD patients and was negative in all samples, while P. gingivalis was detected in 7/10.
• H. pylori–dementia link: More consistent for all-cause dementia than for AD specifically. The dementia association may be driven by vascular cognitive impairment, not amyloid/tau pathology.
• Eradication evidence: One small open-label RCT (Kountouras 2009, n=106) reported MMSE improvement from eradication. No independent double-blind replication.
• Mechanistic hypothesis: OMV-mediated C3-C3aR complement activation in astrocytes; LPC-enriched OMVs may accelerate Aβ aggregation — but human evidence is absent.

Why It Matters for Vitals

• Inflammatory biomarker confound: H. pylori gastritis elevates systemic IL-6, TNF-α; may contribute to chronically elevated CRP baselines used in recovery tracking.
• B12 deficiency: H. pylori can impair B12 absorption; B12 deficiency causes reversible cognitive symptoms and elevates homocysteine — potentially confounds AD presentation.
• Recovery interpretation: Eradication therapy (antibiotics + PPI) itself causes GI disruption and microbiome effects that may transiently affect recovery biometrics.
• Practical guidance: Test for H. pylori for standard GI/B12 indications. Do not recommend eradication solely for cognitive protection.

Proposed Mechanisms

OMV-Mediated CNS Effects

H. pylori OMVs cross the BBB in mice and are taken up primarily by astrocytes, inducing complement C3 upregulation and C3aR activation in glial cells, leading to synaptic dysfunction and Aβ deposition in APP/PS1 mice (PMID:36792546). LPC 18:0 enriched in H. pylori OMVs accelerates Aβ aggregation in vitro (PMID:39516239). See Bacterial OMVs for the shared cross-pathogen mechanism note.

Critical caveat: No study has detected H. pylori OMVs or antigens in human brain tissue or CSF. This mechanism is entirely preclinical.

Systemic Inflammation

H. pylori gastritis drives chronic IL-6, TNF-α elevation. This overlaps with systemic inflammation pathways relevant to Vitals recovery tracking (CRP, IL-6). The inflammatory burden from H. pylori may contribute to cognitive decline via vascular mechanisms rather than direct CNS invasion.

B12 / Homocysteine Pathway

H. pylori can impair gastric acid and intrinsic factor production, reducing B12 absorption. B12 deficiency causes macrocytosis, elevated homocysteine, and cognitive symptoms — potentially reversible. This is the most clinically actionable mechanistic pathway and does not require brain invasion.

Clinical Evidence

Positive (dementia broadly):

• Huang et al. 2019 (PMID:31026327): meta-analysis 25 studies, RR 1.37 (95% CI 1.19–1.58) for dementia risk.
• Du et al. 2025 (PMID:40687714): 41 studies, n=159,220; RR 1.36 (95% CI 1.11–1.67) for all-cause dementia; AD RR 1.43 (CI 1.01–2.02) — borderline.
• Elhady et al. 2025 (PMID:40958121): bidirectional association; OR 1.34 for cognitive dysfunction; OR 3.19 for dementia broadly. No significant link with AD specifically.

Negative / Null:

• Liu et al. 2021 (PMID:34559067): meta-analysis 10 studies; all-cause dementia RR 1.36; no significant AD-specific association in both cohort and case-control sub-analyses.
• Beydoun et al. 2008 (PMID:18378629): prospective NHANES cohort (n=1,608); HR 0.98 (NS) for incident dementia.
• H. pylori was negative in all 10 AD patient CSF samples tested (PMID:30746447).

Critical interpretive points:

• Most positive meta-analyses pool all dementia subtypes — vascular dementia has stronger and more biologically plausible association with chronic inflammation than AD.
• The ORs are modest (1.3–1.7) — precisely the range most susceptible to residual confounding (SES, healthcare access, diet, smoking).
• Prevalence paradox: ~44% global H. pylori prevalence vs ~10% AD prevalence in over-65s — if causal, the population attributable fraction should produce far higher effect sizes.

Eradication Therapy Safety

Standard regimens:

• First-line triple: PPI + clarithromycin + amoxicillin × 14 days (~70% eradication)
• Bismuth quadruple: PPI + bismuth + tetracycline + metronidazole × 14 days (~93% eradication; preferred if clarithromycin resistance suspected)
• Vonoprazan dual (where available): vonoprazan + amoxicillin — comparable efficacy, fewer side effects

Key safety considerations for Vitals context:

• Clarithromycin: GI upset, rare hepatotoxicity; significant CYP3A4 drug-drug interactions
• Metronidazole: GI upset, metallic taste, rare seizures
• Tetracycline: photosensitivity, esophageal irritation; generally avoided in elderly
• Bismuth: renal accumulation risk in elderly/renal impairment
• Probiotic (S. boulardii) adjunct: ~10% absolute increase in eradication rate; reduces antibiotic-associated diarrhea
• Short-term PPI (14 days): low risk; long-term concerns not relevant for eradication courses

See H. pylori eradication protocols for full detail. Do not initiate eradication solely for cognitive protection.

Limitations of Current Evidence

1. H. pylori has never been demonstrated in AD brain tissue
2. No large double-blind RCT of eradication for AD prevention or treatment
3. The association is stronger for all-cause dementia than for AD specifically — may reflect vascular mechanisms
4. Modest ORs (1.3–1.7) in the range of residual confounding
5. Prevalence paradox: too common globally to be a specific AD driver
6. B12 deficiency and gastric atrophy may explain much of the cognitive association

What Not to Recommend

• Do not recommend H. pylori eradication solely for AD prevention or treatment — not evidence-supported
• Do not endorse mastic gum or other supplements as treatments targeting H. pylori for cognitive purposes
• Do not use serology alone for active infection detection (cannot distinguish past from current infection)
• Do not stop standard AD medications based on H. pylori or oral health data

Related Notes

• Bacterial OMVs — OMV CNS crossing mechanism (cross-cutting)
• Infectious Agents MOC — navigation hub

References

• PMID:30746447 — Dominy et al. 2019, Sci Adv (H. pylori negative control in CSF)
• PMID:40958121 — Elhady et al. 2025, Eur J Med Res (no AD-specific link; bidirectional dementia)
• PMID:40687714 — Du et al. 2025, Front Med (dementia broadly; borderline AD)
• PMID:34559067 — Liu et al. 2021, Aging (no significant AD-specific association)
• PMID:18378629 — Beydoun et al. 2008, NHANES prospective (HR 0.98, NS)
• PMID:36792546 — Xie et al. 2023, J Extracell Vesicles (OMV → C3-C3aR in mice)
• PMID:39516239 — Meng et al. 2024, Commun Biol (OMV → Aβ in APP/PS1 mice)
• PMID:19240960 — Kountouras et al. 2009, J Neurol (small open-label eradication RCT)
• PMID:29181894 — Doulberis et al. 2018, Helicobacter (oral-gastric H. pylori reservoir)